CHARLOTTE BUDZIK: Open Payments
NPI 1811975303 · WASHINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,175 in 217 payments from 14 companies in 2025. Trend: 2023 $1,084 · 2024 $1,439 · 2025 $5,175
Food & beverage: $5,091Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 52 | $1,345 |
| Janssen Biotech, Inc. | 28 | $784 |
| Madrigal Pharmaceuticals | 25 | $621 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 26 | $544 |
| PFIZER INC. | 20 | $466 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $399 |
| GENZYME CORPORATION | 7 | $269 |
| Ardelyx, Inc. | 11 | $254 |
| Phathom Pharmaceuticals, Inc. | 13 | $202 |
| Organon LLC | 4 | $94 |
Products named: TREMFYA, REZDIFFRA, RINVOQ, XIFAXAN, SKYRIZI, XELJANZ, ENTYVIO, DUPIXENT.
Industry payments across PA — which companies pay providers there.
